Title page (Article)

SARS-CoV-2 specific T cell and humoral immune responses upon vaccination with BNT162b2: A 9 months longitudinal study

Authors:

Junko S. Takeuchi*[1], Ami Fukunaga*[2], Shohei Yamamoto*[2], Akihito Tanaka[3], Kouki Matsuda[4], Moto Kimura[1], Azusa Kamikawa[1], Yumiko Kito[1], Kenji Maeda[4], Gohzoh Ueda[5], Tetsuya Mizoue[2], Mugen Ujiie[6], Hiroaki Mitsuya[4], Norio Ohmagari[6], Wataru Sugiura[7]

Affiliations:

[1] Department of Academic-Industrial Partnerships Promotion, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo 162-8655, Japan

[2] Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo 162-8655, Japan

[3] Department of Laboratory Testing, Center Hospital of the National Center for the Global Health and Medicine, Tokyo 162-8655, Japan

[4] Department of Refractory Viral Infection, Research Institute, National Center for Global Health and Medicine, Tokyo 162-8655, Japan

[5] Division of Core Diagnostics, Abbott Japan LLC, Tokyo 108-6305, Japan

[6] Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo 162-8655, Japan

[7] Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo 162-8655, Japan

*Equal contribution as first author

Corresponding Author

Wataru Sugiura

Center for Clinical Sciences, National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjuku-ku, Tokyo 162-8655, Japan

TEL: +81-3-3202-7181, Fax: +81-3-5273-6850

E-mail: wsugiura@hosp.ncgm.go.jp

Running title: T cell and humoral immune responses to BNT162b2 vaccine

Keywords: SARS-CoV-2; COVID-19; BNT162b2 vaccine; humoral immunity; T cell immunity; neutralizing antibody

Word counts of Abstract: 200 words

Word counts of text: 3,416 words

Abstract (200 words)

Introduction. The humoral and cellular immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) upon coronavirus disease 2019 (COVID-19) vaccination remain to be clarified. Hence, we aimed to investigate the long-term chronological changes in SARS-CoV-2 specific IgG antibody, neutralizing antibody, and T cell responses during and after receiving the BNT162b2 vaccine.

Methods. We performed serological, neutralization, and T cell assays among 100 hospital workers aged 22-73 years who received the vaccine. We conducted seven surveys up to eight months after the second vaccination dose.

Results. SARS-CoV-2 spike protein-specific IgG (IgG-S) titers and T cell responses increased significantly following the first vaccination dose. The highest titers were observed on day 29 and decreased gradually until the end of the follow-up period. There was no correlation between IgG-S and T cell responses. Notably, T cell responses were detected on day 15, earlier than the onset of neutralizing activity.

Conclusions. This study demonstrated that both IgG-S and T cell responses were detected before acquiring sufficient levels of SARS-CoV-2 neutralizing antibodies. These immune responses are sustained for approximately six–ten weeks but not for seven months or later

following the second vaccination, indicating the need for the booster dose (i.e., third vaccination) .

INTRODUCTION

The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has imposed a tremendous burden on global morbidity and mortality since December 2019 [1]. In response to the COVID-19 pandemic, multiple vaccines have been rapidly developed and tested for their efficacy and safety. BNT162b2, an mRNA-based SARS-CoV-2 vaccine (Pfizer-BioNTech), was the first COVID-19 vaccine listed for emergency use and COVAX roll-out by the World Health Organization, with a 95% efficacy in clinical trials [2]. To examine the effectiveness of the vaccine, a growing body of studies has investigated SARS-CoV-2 specific humoral and cellular responses following vaccination. Studies have shown that a two-dose regimen of BNT162b2 induces SARS-CoV-2 specific humoral and cellular responses, such as immunoglobulin G (IgG) antibodies [3-5], neutralizing antibodies [6-8], as well as $CD4^+$ and $CD8^+$ T cells [6,7,9].

However, some important issues remain to be addressed. First, little is known about neutralizing antibodies and cellular immune responses against SARS-CoV-2 following COVID-19 vaccination compared to the evidence on IgG antibodies. Second, epidemiological evidence on temporal changes in humoral and cellular responses and their associated factors, and use of longitudinal data with repeated measures, is limited. Third, studies on the correlation between humoral and cellular responses are scarce. Investigation of humoral and

74 cellular immune responses during and after the COVID-19 vaccination regimen is required to
75 understand its effectiveness, the duration of effectiveness, and the differences in such
76 responses across varying background factors.
77 Hence, this longitudinal study aimed to investigate chronological changes in IgG
78 antibody, neutralizing antibody, and T cell responses, along with their associated factors, during
79 and after the BNT162b2 vaccination regimen, in hospital workers of a national medical
80 institution in Japan.
81
82 **METHODS**
83 ***Patient Consent Statement***
84 Written informed consent was obtained from all the participants before the baseline survey. The
85 study protocol was approved by the Ethics Committee of NCGM, Japan (approval number:
86 NCGM-A-004175-00).
87
88 ***Study Design and Participants***
89 We performed a longitudinal study among the staff of the National Center for Global Health and
90 Medicine (NCGM), a national medical institution designated for research and treatment of
91 infectious diseases, between March and December 2021, after the start of the vaccination

program. We recruited 100 volunteers via e-mail from NCGM staff aged 20 years or above who were scheduled to receive the first COVID-19 vaccination dose on the dates of the baseline survey. None of the participants were on immunosuppressive medication or had a history of COVID-19. All participants received the mRNA-based SARS-CoV-2 vaccine BNT162b2 (Pfizer-BioNTech) according to the standard protocol (two doses of 30 μg administered three weeks apart) [6,10]. A total of seven surveys were conducted on the following schedule: day 1 (immediately after the first dose), day 15, day 29 (seven days after the second dose), day 61, day 82–96 (at the time of periodic health checkup), day 224–232, and day 263 (~ eight months after the second dose).

Cells and Viruses

$VeroE6_{TMPRSS2}$ cells [11] were obtained from the Japanese Collection of Research Bioresources (JCRB) Cell Bank (Osaka, Japan). $VeroE6_{TMPRSS2}$ cells were maintained in DMEM supplemented with 10% FCS, 100 μg/mL penicillin, 100 μg/mL streptomycin, and 1 mg/mL G418. The SARS-CoV-2 NCGM-05-2N strain (SARS-CoV-$2_{05\text{-}2N}$) was isolated from the nasopharyngeal swab of a patient with COVID-19 admitted to the NCGM hospital [8,12].

110 ***Serological Assays***

111 We performed three serological assays to detect the IgM and IgG antibodies against SARS-
112 CoV-2 spike protein (IgM-S and IgG-S, respectively) and IgG antibodies against SARS-CoV-2
113 nucleocapsid protein (IgG-N). The presence of IgG-N antibodies can indicate SARS-CoV-2
114 infection prior to the study and during follow-up, regardless of the vaccination status. In
115 contrast, the presence of IgM-S and IgG-S indicates the previous infection and/or humoral
116 immunity following vaccination, because BNT162b2 is constructed to express the full-length
117 spike protein.

118 To detect IgG-S, the AdviseDx SARS-CoV-2 IgG II assay was performed using the
119 Abbott ARCHITECT® following the manufacturer's protocol. The assay detects the IgG
120 antibodies against the receptor-binding domain (RBD) of the S1 subunit of the SARS-CoV-2
121 spike protein using chemiluminescent microparticle immunoassay (CMIA). The resulting
122 chemiluminescence in relative light units (RLU) indicates the strength of the response, which in
123 turn reflects the quantity of IgG-S present. We considered 50 AU/mL and above as the cutoff for
124 seropositivity, as recommended by the vendor. We also tested 4,160 AU/mL as the cutoff, given
125 that this threshold may correspond to a 95% probability of sufficient neutralizing activity [13].
126 This quantitative IgG-S test could evaluate an individual's humoral response to vaccines.

To detect IgM-S, the AdviseDx SARS-CoV-2 IgM assay, based on semi-quantitative CMIA, was performed using the Abbott ARCHITECT® according to the manufacturer's instructions. We defined the seropositive cutoff as 1.0 (index value) and above, according to the vendor's recommendation.

For the IgG-N assay, the Abbott ARCHITECT® SARS-CoV-2 anti-N IgG assay based on semi-quantitative CMIA was performed. We considered the index values of 1.40 and above as seropositive cutoff according to the manufacturer's instructions.

Neutralization Assay

An enzyme-linked immunosorbent assay (ELISA)-based semi-quantitative neutralization assay was conducted at three points of the survey (day 15, 29, and 61). It was performed at a single serum dilution according to the manufacturer's instructions (SARS-CoV-2-NeutraLISA, Euroimmun, Germany). Antibody-mediated inhibition of soluble human receptor protein (angiotensin-converting enzyme 2, hACE2) binding to the RBD of the viral S1 region was tested. The surrogate neutralizing capacity was calculated as the percentage of inhibition (% IH): IH = 100% - (extinction of the respective sample × 100% / extinction of the blank). An IH<20% was considered as negative, IH ≥20% to <35% intermediate, and IH ≥35% positive. Each serum sample was tested in duplicates.

145 The *in vitro* viral experiment-based neutralizing activity was determined

146 by quantifying the serum-mediated suppression of the cytopathic effect (CPE) of the SARS-

147 CoV-2 strain in $VeroE6_{TMPRSS2}$ cells, as previously described [8], but with minor modifications. In

148 brief, each serum was four-fold serially diluted in the culture medium. The diluted sera were

149 incubated with 100 $TCID_{50}$ (50% tissue culture infectious dose) of viruses at 37 °C for

150 20 minutes. Then, the serum-virus mixtures were inoculated into $VeroE6_{TMPRSS2}$ cells (1.0 ×

151 10^4/well) in 96-well plates. After culturing the cells for three days, the CPE levels observed in

152 SARS-CoV-2-exposed cells were determined by the WST-8 assay using the Cell Counting Kit-8

153 (Dojindo, Kumamoto, Japan). The serum dilution that resulted in 50% inhibition of CPE was

154 defined as a 50% neutralization titer (NT_{50}). Each serum sample was tested in duplicates.

155

156 ***IFN-γ Whole Blood Assay***

157 SARS-CoV-2 specific $CD4^+$ and $CD8^+$ T cell responses were investigated at six points (day 1,

158 15, 29, 61, 224–232, and 263). We quantified T cell-produced interferon-gamma (IFN-γ) in

159 response to SARS-CoV-2 spike peptides using QuantiFERON SARS-CoV-2 RUO (QIAGEN,

160 Germany) according to the manufacturer's instructions. Briefly, 5 mL of whole blood specimens

161 were collected in a collection tube containing sodium heparin (VP-H050K, Terumo, Japan) at

162 six time points during the vaccination regimen. The collected blood samples were stored at

163 room temperature for no more than 2–3 hours, and 1 mL of the sample was transferred to each

164 QuantiFERON blood collection tube: Nil (negative control), mitogen (positive control), Ag1

165 and Ag2 (spike protein antigens). Ag1 induces a $CD4^+$ T cell response, and Ag2 stimulates both

166 CD4+ and CD8+ T cell responses. The four tubes were inverted to coat the sides of the tubes

167 and placed in a 37 °C incubator for 16–24 hours. Subsequently, the plasma samples were

168 harvested following centrifugation, stored at -80 °C, and tested for the release of IFN-γ from

169 stimulated T cells by QuantiFERON ELISA with microplate reader SpectraMax iD5 (Molecular

170 Devices, USA). The quantitative IFN-γ concentration (IU/mL) was analyzed using the

171 QuantiFERON R&D Analysis Software (version 5.3.0). Greater than or equal to 0.20 IU/mL

172 IFN-γ concentration was used to define positive T cell responses, as previously reported [14].

173

174 ***Statistical Analysis***

175 To examine the difference in changes of IgG-S titers across background factors (age, sex, and

176 body mass index [BMI]), we fitted the mixed model of repeated measures with an unstructured

177 covariance matrix. Background factors were treated as categorical variables in the models: age

178 (<40 or ≥40 years), sex (men or women), and BMI (<25 or ≥25 kg/m^2). Log-transformed IgG-S

179 titers were used as the dependent variable. We set each background factor, time, and interaction

180 terms as fixed factors, and individual identifiers and time as random factors in the model. In all

models, we adjusted for age and sex as covariates. We estimated the mean log-transformed IgG-S titers with 95% confidence intervals (CIs); then, we back-transformed them and presented them as geometric means titers. To compare the mean differences of IgG-S titers between background factors at each time point, we used the Wald test. As three participants received their second vaccination on an irregular schedule (more than four weeks after the first dose), we treated their antibody titers data from day 29 to day 263 as missing values. We repeated these analyses for spike-specific T cell responses.

To examine the correlation between IgG-S titers and spike-specific T cell responses at each time point (day 1, 15, 29, 61, 224–232, and 263), we conducted Spearman's rank correlation test.

Statistical analyses were conducted using STATA version 17.0 and GraphPad Prism 9.3.0.

RESULTS

Study participants

Table 1 presents participants' background information. The participants included 32 men and 68 women with a mean age (standard deviation) of 42.7 (11.7) years (range: 22–73 years). Major occupations included administrative staff (19%), nurses (17%), doctors (7%), allied healthcare

professionals (4%), and other occupations (e.g., researchers and research assistants) (53%).

Antibody Titers and Neutralizing Activity

Table 2 and Figures 1–2 show the humoral and cellular responses during and after the vaccination regimen. All participants were seronegative for IgG-S, IgG-N, and IgM-S on day 1 (Figure 1A–C). These observations were consistent with the fact that none of the participants had a history of COVID-19. IgG-S titers were significantly higher than the baseline value in the later time points (Table 2). We observed the highest IgG-S titers on day 29 (seven days after the second dose), with a median of 20,582 AU/mL (interquartile range [IQR] 11,372–29,747), followed by a time-dependent decrease: median of 9,649 (IQR 5,168–13,143) on day 61, 5,419 (IQR 2,854–8,209) on day 82–96, 780 (IQR 439–1,345) on day 224–232, and 784 (IQR 301–1,038) on day 263. For IgG-S, 99% (99/100) of the participants were seropositive on day 15 following the first dose, and all participants were seropositive on day 29 (seven days after the second dose) and remained positive during follow-up until day 263. Regarding the surrogate measures of neutralizing activity defined by the IgG-S titers (cutoff of 4,160 AU/mL), no participants were seropositive on day 15, while 96% became positive on day 29; this decreased to 81% and 58% on day 61 and day 82–96, respectively (Table 2). With longer follow-up, all participants became seronegative on day 224–232 and day 263 (< 4,160 AU/mL). We also tested

217 neutralizing activity using the ELISA-based semi-quantitative neutralization assay, which
218 showed that 37% of the participants had sufficient neutralizing activity on day 15, while all
219 participants had sufficient levels of neutralizing activity on day 29 and 61 (Table 2 and Figure
220 1D).

221 There was a significant association of younger age (<40 years) with higher IgG-S
222 titers throughout the five survey time points (P<0.01) (Figure 4A and Supplementary Table S1).
223 Although we did not observe a statistically significant difference in IgG-S titers with respect to
224 sex or BMI, females or individuals with normal BMI tended to have higher IgG-S titers than
225 males or those with BMI ≥25 kg/m^2 throughout the surveys (Figure 4B–C and Supplementary
226 Table S1).

227

228 ***Vaccine-Induced T cell Responses***

229 None of the participants had T cell responses against SARS-CoV-2 antigens on day 1, indicating
230 that none of them were infected with SARS-CoV-2 prior to the study. Following the first
231 vaccination dose, T cell responses increased (0.85 and 1.72 IU/mL for Ag1-Nil and Ag2-Nil,
232 respectively) and peaked after the boost on day 29 (5.76 and 9.68 IU/mL for Ag1-Nil and Ag2-
233 Nil, respectively), but decreased to day 61 (1.58 and 2.76 IU/mL for Ag1-Nil and Ag2-Nil,
234 respectively), day 224–232 (0.42 and 0.91 IU/mL for Ag1-Nil and Ag2-Nil, respectively), and

day 263 (0.25 and 0.48 IU/mL for Ag1-Nil and Ag2-Nil, respectively) (Table 2 and Figure 2). Overall, higher values for T cell response were obtained for Ag2-Nil ($CD4^+$ and $CD8^+$) than Ag1-Nil ($CD4^+$), indicating that both $CD4^+$ and $CD8^+$ T cells serve as cellular immunity induced by the COVID-19 vaccination.

While analyzing the association between background factors (age, sex, and BMI) and T cell responses, we did not observe a statistically significant difference in IFN-γ produced by T cells by age or BMI at all time points (data not shown). While men were significantly associated with a higher IFN-γ production by $CD4^+$ T cells on day 29 ($P < 0.05$), this association was not observed when one high outlier was excluded (Supplementary Figure S1).

Further, we found no correlations between IgG-S and IFN-γ production in $CD4^+$ (Figure 3A) and $CD4^+ + CD8^+$ T cells (Figure 3B) throughout the surveys, except on day 15, and significantly weak correlations were observed on day 15 (Spearman rank coefficient [rho] = 0.83; $p < 0.01$ and rho = 0.29; $p < 0.01$ for $CD4^+$ and $CD4^+ + CD8^+$, respectively).

DISCUSSION

In this study, we documented the IgG-S antibody and T cell responses on day 15 following the first dose of the BNT162b2 vaccine. We found that both IgG-S antibody and T cell responses peaked seven days after the second dose (day 29) and gradually declined until the end of the

follow-up period. Sufficient levels of the IgG-S antibody were maintained for over six to ten weeks following the second dose of BNT162b2 vaccination, but all participants became seronegative at seven months or later after the second dose when 4,160 AU/mL was used as the cutoff. It is noteworthy that T cell responses were detected earlier than the neutralizing activity. However, we did not observe any statistically significant correlation between humoral and cellular immune responses throughout the survey period.

We observed that IgG-S titers on day 15 and day 29 were 211-fold and 7,916-fold higher, respectively, than that of day 1, and it decreased by 53.1%, 73.7%, and 96.2% on day 61 (39 days after the second dose), day 82–96 (60–74 days after the second dose), and day 263 (eight months after the second dose), respectively, compared to the peak on day 29. Similar to our findings on chronological changes in IgG-S titers, a multicenter prospective study among health care professionals at multiple time points (day 0, 14, 28, 42, 56, and 90) showed that the antibody response (measured as IgG-S) was detected on day 14 following the first dose and reached a peak between day 14 and 28 (the second dose was administered on day 21). Further, the response decreased by 43% on day 90 compared to the highest antibody response [3]. As for longer follow-up time period, another study in a large cohort of 4,868 participants showed that IgG-S titers decreased by 94.5% and waned at six months after the second dose compared to the peak [15], which is consistent with our finding.

271 In contrast to the IgG-S antibody response, the majority of participants did not attain
272 sufficient levels of neutralizing antibodies against SARS-CoV-2 on day 15, as assessed by
273 ELISA-based neutralization assay (37%) and IgG-S titers with a cutoff of 4,160 AU/mL (0%).
274 However, nearly 100% of participants were positive for neutralizing activity in both assays on
275 day 29. These results suggest that individuals might attain sufficient neutralizing antibodies
276 against SARS-CoV-2 seven days after the second dose of the BNT162b2 vaccine. Further
277 investigations should be tested in neutralizing activity for a longer follow-up time period, given
278 that the proportion of those with sufficient neutralizing antibodies declined after the peak when
279 it was assessed with IgG-S titers.

280 In the analysis of investigating the changes of IgG-S titers across background factors,
281 younger age was significantly associated with higher IgG-S titers throughout the follow-up
282 period. This finding accords with previous studies that showed the association between age and
283 antibody responses [5,16,17]. It has been suggested that age is an important contributing factor for
284 vaccine-induced humoral immune responses. Similarly, our findings and previous evidence
285 suggest that older individuals are vulnerable to lower IgG-S titers throughout and after COVID-
286 19 vaccination compared to younger individuals.

287 The present study showed that T cell responses were detected on day 15 following the
288 first dose of the vaccination, similar to the antibody responses. This early induction of T cell

289 responses agrees with the findings of a cohort study of 20 Singapore healthcare workers who
290 received the BNT162b2 vaccine [7], and a study of individuals who received the Moderna
291 mRNA-1273 vaccine [14]. Notably, we observed that T cell responses were detectable earlier than
292 the neutralizing antibodies, consistent with a previous report [7]. A clinical trial evaluating the
293 efficacy of BNT162b2 indicated that the vaccine might prevent the onset of COVID-19
294 approximately 12 days after the first dose [10]. These observations suggest that early T cell
295 responses, detected on day 15 and earlier than neutralizing antibodies, may contribute to the
296 vaccine's efficacy. Interestingly, early T cell responses have also been reported in COVID-19
297 cases. A review paper by Bertoletti *et al*. suggested that T cells are detected within seven–ten
298 days after infection [18]. Moreover, early induction of IFN-γ-producing SARS-CoV-2-specific T
299 cells was observed in patients with mild symptoms [19]. Rapid and functional induction of T cell
300 immune responses may play a critical role in both COVID-19 cases and vaccinated individuals.
301 However, we did not find any evidence of an association between background factors
302 (age, sex, and BMI) and T cell responses. A recent study reported that the production of IFN-γ
303 from SARS-CoV-2 spike-specific T cells was lower in older vaccinated participants (≥ 80 years
304 old) [20]. In our study, all participants were younger than 80 years old (the maximum age was 73
305 years), which might explain the null finding on the association between age and T cell
306 responses.

We did not observe any statistically significant correlation between IgG-S and IFN-γ production in $CD4^+$ and $CD4^+$ + $CD8^+$ T cells. Some participants had higher IFN-γ values with low or moderate IgG-S levels and vice versa. However, the correlation between SARS-CoV-2 spike-specific humoral and cellular immune responses remains controversial [7,21]. This discrepancy can be explained by the pre-existence of cross-reactive memory T cells against SARS-CoV-2. Interestingly, previous studies have reported that long-lasting memory T cells, induced by common cold coronaviruses, can display robust cross-reactivity to SARS-CoV-2 [22,23]. However, the participants in this study did not show T cell responses against SARS-CoV-2 spike antigens on day 1, implying that none of the participants had pre-existing cross-reactive memory T cells against SARS-CoV-2.

The strengths of the present study include the longitudinal design with repeated measures of antibodies and T cell responses during and after the COVID-19 vaccination regimen. However, this study has several limitations. First, our study was conducted in a small-scale cohort of hospital workers in a single medical institution in Japan; thus, our findings might not be generalized to other settings. Second, the sufficient level of neutralizing activity or cellular immunities that is enough to protect against SARS-CoV-2 infection is not well known. In this study, sufficient neutralizing activity levels were defined as IH ≥35% in ELISA-based semi-quantitative neutralization assay (NeutraLISA), and the positive results evaluated by

NeutraLISA spanned a wide range of values when the samples were analyzed by an *in vitro* virological experiment (summarized in Supplementary Figure S2). Further studies are warranted to determine sufficient levels of SARS-CoV-2 IgG antibody, neutralizing antibody, and T cell responses against SARS-CoV-2 infection and the duration of immunity induced by the vaccine.

In conclusion, our study demonstrated that BNT162b2 vaccination induces SARS-CoV-2 specific IgG-S antibody and T cell responses, which were detected on day 15 following the first dose and earlier than the onset of neutralizing activity, peaked after the second dose and gradually declined over time. Sufficient levels of these responses against SARS-CoV-2 infection were maintained for over six–ten weeks but not for seven months or later following the second dose of BNT162b2 vaccination, which may indicate the need for the booster dose. Our study contributes to a better understanding of the humoral and cellular immune responses upon COVID-19 vaccination.

DATA AVAILABILITY

The data are not publicly available due to ethical restrictions for public deposition but available from the Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan (corresponding author: Wataru Sugiura, wsugiura@hosp.ncgm.go.jp) for researchers who meet the criteria to access the data.

343 **REFERENCES**

344 1 WHO Coronavirus Disease (COVID-19) Dashboard (https://covid19.who.int/).

345 2 Dagan, N. *et al.* BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass
346 Vaccination Setting. *N Engl J Med* **384**, 1412-1423, doi:10.1056/NEJMoa2101765
347 (2021).

348 3 Favresse, J. *et al.* Antibody titres decline 3-month post-vaccination with BNT162b2.
349 *Emerg Microbes Infect* **10**, 1495-1498, doi:10.1080/22221751.2021.1953403 (2021).

350 4 Zaffina, S. *et al.* Induction of immune response after SARS-CoV-2 mRNA BNT162b2
351 vaccination in healthcare workers. *J Virus Erad* **7**, 100046,
352 doi:10.1016/j.jve.2021.100046 (2021).

353 5 Kageyama, T. *et al.* Antibody responses to BNT162b2 mRNA COVID-19 vaccine and
354 their predictors among healthcare workers in a tertiary referral hospital in Japan. *Clin*
355 *Microbiol Infect* **27**, 1861 e1861-1861 e1865, doi:10.1016/j.cmi.2021.07.042 (2021).

356 6 Sahin, U. *et al.* BNT162b2 vaccine induces neutralizing antibodies and poly-specific T
357 cells in humans. *Nature*, doi:10.1038/s41586-021-03653-6 (2021).

358 7 Kalimuddin, S. *et al.* Early T cell and binding antibody responses are associated with
359 COVID-19 RNA vaccine efficacy onset. *Med (N Y)* **2**, 682-688 e684,
360 doi:10.1016/j.medj.2021.04.003 (2021).

361 8 Maeda, K. *et al.* Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response
362 with adverse effects and immune kinetics in BNT162b2-vaccinated individuals. *Sci Rep*
363 **11**, 22848, doi:10.1038/s41598-021-01930-y (2021).

364 9 Martinez-Gallo, M. *et al.* Commercialized kits to assess T-cell responses against SARS-
365 CoV-2 S peptides. A pilot study in health care workers. *Med Clin (Barc)*,
366 doi:10.1016/j.medcli.2021.09.013 (2021).

367 10 Polack, F. P. *et al.* Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N*
368 *Engl J Med* **383**, 2603-2615, doi:10.1056/NEJMoa2034577 (2020).

369 11 Matsuyama, S. *et al.* Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing
370 cells. *Proc Natl Acad Sci U S A* **117**, 7001-7003, doi:10.1073/pnas.2002589117 (2020).

371 12 Maeda, K. *et al.* Neutralization of SARS-CoV-2 with IgG from COVID-19-
372 convalescent plasma. *Sci Rep* **11**, 5563, doi:10.1038/s41598-021-84733-5 (2021).

373 13 Ebinger, J. E. *et al.* Antibody responses to the BNT162b2 mRNA vaccine in individuals
374 previously infected with SARS-CoV-2. *Nat Med* **27**, 981-984, doi:10.1038/s41591-021-
375 01325-6 (2021).

376 14 Jaganathan, S. *et al.* Preliminary Evaluation of QuantiFERON SARS-CoV-2 and
377 QIAreach Anti-SARS-CoV-2 Total Test in Recently Vaccinated Individuals. *Infect Dis*

Ther **10**, 2765-2776, doi:10.1007/s40121-021-00521-8 (2021).

15 Levin, E. G. *et al.* Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. *N Engl J Med* **385**, e84, doi:10.1056/NEJMoa2114583 (2021).

16 Muller, L. *et al.* Age-dependent immune response to the Biontech/Pfizer BNT162b2 COVID-19 vaccination. *Clin Infect Dis*, doi:10.1093/cid/ciab381 (2021).

17 Terpos, E. *et al.* Age-dependent and gender-dependent antibody responses against SARS-CoV-2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine. *Am J Hematol* **96**, E257-E259, doi:10.1002/ajh.26185 (2021).

18 Bertoletti, A., Tan, A. T. & Le Bert, N. The T-cell response to SARS-CoV-2: kinetic and quantitative aspects and the case for their protective role. *Oxford Open Immunology* **2**, doi:10.1093/oxfimm/iqab006 (2021).

19 Tan, A. T. *et al.* Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. *Cell Rep* **34**, 108728, doi:10.1016/j.celrep.2021.108728 (2021).

20 Collier, D. A. *et al.* Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. *Nature* **596**, 417-422, doi:10.1038/s41586-021-03739-1 (2021).

21 Parry, H. M. *et al.* Single Vaccination with BNT162b2 or ChAdOx1 in Older People Induces Equivalent Antibody Generation but Enhanced Cellular Responses after ChAdOx1. *SSRN Electronic Journal*, doi:10.2139/ssrn.3825573 (2021).

22 Mateus, J. *et al.* Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. *Science* **370**, 89-94, doi:10.1126/science.abd3871 (2020).

23 Grifoni, A. *et al.* Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. *Cell* **181**, 1489-1501 e1415, doi:10.1016/j.cell.2020.05.015 (2020).

ACKNOWLEDGMENTS

We thank the members of the study group (Yusuke Oshiro, Natsumi Inamura, Takashi Nemoto, Haruka Osawa, Maki Konishi, and Nobumi Katayama) for their support. This work was funded by Abbott Japan (grant number 20C050), the NCGM COVID-19 Gift Fund (grant number 19K059), the Japan Health Research Promotion Bureau Research Fund (grant number 2020-B-09), AMED (grant number JP20nk0101627 and JP21nf0101627), and a grant from the National Center for Global Health and Medicine (grant number 21A006).

AUTHOR CONTRIBUTIONS

WS, GU, and TM designed the study concept and methodology. AF, SY, and TM performed project administration and developed software. JST, AT, Kouki M, AK, and YK performed experiments. JST, AF, and SY analyzed and validated the data, and wrote the original draft manuscript. WS, NO, HM, MU, TM, MK, and Kenji M provided resources and contributed to supervision. All authors read and approved the final manuscript.

COMPETING INTERESTS

The authors (except Gohzoh Ueda) declare no conflict of interest. Gohzoh Ueda is one of employees of Abbott Japan, which provided the antibody assay reagents and funding for the

present study. The funders did not play any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.

FIGURE LEGENDS

Figure 1. Humoral responses during and after BNT162b2 mRNA-based SARS-CoV-2 vaccination regimen. (A-C) Humoral responses in serum on day 1 (immediately after the first dose), day 15, day 29 (seven days after the second dose), day 61, day 82–96, day 224–232, and day 263. IgG antibodies against SARS-CoV-2 spike protein (A), nucleocapsid (B), and IgM against spike protein (C) were measured using chemiluminescent microparticle immunoassay (CMIA). An ELISA-based semi-quantitative neutralization assay was also performed (D). Dashed lines indicate the cutoff for each assay. All data were represented as line graphs using GraphPad Prism 9.3.0. Black line indicates 4,160 AU/mL as the cutoff, given that this threshold may correspond to a 95% probability of sufficient neutralizing activity.

Figure 2. SARS-CoV-2 spike specific T cell response during and after BNT162b2 mRNA-based SARS-CoV-2 vaccination regimen. The release of IFN-γ from stimulated $CD4^+$ T cells (A) and both $CD4^+$ and $CD8^+$ T cells (B) with SARS-CoV-2 spike peptides using QuantiFERON SARS-CoV-2 RUO. All data were represented as line graphs using GraphPad Prism 9.3.0. Dashed lines indicate the cutoff for the assay.

Figure 3. Correlation between SARS-CoV-2 spike specific IgG titers and T cell responses at each time point. Spearman's rank correlation test was conducted using STATA version 17.0. (A) Correlation between IgG-S titer and spike-specific $CD4^+$ T-cell responses. (B) Correlation between IgG-S titer and spike-specific $CD4^+$ and $CD8^+$ T cell responses.

Figure 4. SARS-CoV-2 spike specific IgG titers by background factors. Wald test was used to compare the mean differences of IgG-S titers between background factors at each time point using STATA version 17.0. (A) SARS-CoV-2 spike specific IgG titers by age (<40 or ≥40 years) (B) SARS-CoV-2 spike specific IgG titers by sex (men or women) (C) SARS-CoV-2 spike specific IgG titers by BMI (<25 or ≥25 kg/m^2).

Table 1. Participants' characteristics (n = 100)

	Overall (n = 100)	
	Mean (SD)	**%**
Age, years	42.7 (11.7)	
<40		42
≥40		58
Sex		
Men		32
Women		68
Job category		
Doctors		7
Nurses		17
Allied healthcare professionals		4
Administrative staff		19
Others (e.g., researchers, research assistants)		53
Department		
COVID-19-related department		6
The other medical department		31
Non-medical department		63
Body mass index, kg/m^2	22.1 (3.2)	
<25		83
≥25		17

SD: standard deviation.

Table 2. Humoral and cellular immune responses during and after BNT162b2 mRNA-based SARS-CoV-2 vaccination regimen

	Days after First Vaccine Dose						
	Day 1 (n = 100)	**Day 15 (n = 100)**	**Day 29 (n = 97)**	**Day 61 (n = 97)**	**Day 82–96 (n = 96)**	**Day 224–232 (n = 66)**	**Day 263 (n = 19[§], 14[‖])**
IgG-S (AU/mL)	2.6 (1.43–4.40)	550[*] (277–1,013)	20,582[*†] (11,372–29,747)	9,649[*‡] (5,168–13,143)	5,419[*‡] (2,854–8,209)	780[*‡] (439–1,345)	784[*‡] (301–1,038)
Seropositive (≥50)	0%	99%	100%	100%	100%	100%	100%
Seropositive (≥4,160)	0%	0%	96%	81%	58%	0%	0%
IgG-N (S/C)	0.07 (0.02–0.18)	0.07 (0.02–0.17)	0.08 (0.03–0.19)	0.05 (0.02–0.11)	0.07 (0.02–0.14)	0.07 (0.03–0.14)	0.02 (0.02–0.04)
Seropositive (≥1.40)	0%	0%	0%	0%	0%	0%	0%
IgM-S (S/C)	0.04 (0.03–0.08)	0.79[*] (0.45–1.44)	2.78[*†] (1.51–4.51)	0.75[*‡] (0.48–1.52)	– –	0.11[*‡] (0.07–0.29)	0.15[*‡] (0.08–0.25)
Seropositive (≥1.00)	0%	43%	91%	40%	–	3%	0%
IFN-γ CD4$^+$ Ag1-Nil (IU/mL)	0.00 (-0.01–0.01)	0.85[*] (0.37–1.80)	5.76[*†] (2.98–11.29)	1.58[*‡] (0.57–3.22)	– –	0.42[*‡] (0.15–1.32)	0.25[*‡] (0.08–0.88)
Positive (≥0.20)	0%	84%	100%	91%	–	67%	57%
IFN-γ CD4$^+$ and CD8$^+$ Ag2-Nil (IU/mL)	0.00 (-0.01–0.01)	1.72[*] (0.58–3.17)	9.68[*†] (5.38–16.85)	2.76[*‡] (0.85–6.57)	– –	0.91[*‡] (0.28–1.96)	0.48[*‡] (0.24–1.78)
Positive (≥0.20)	0%	92%	100%	96%	–	88%	86%
NeutraLISA (Inhibition %)	– –	29[*] (13–45)	99[*†] (98–100)	98[*‡] (93–99)	– –	– –	– –
Positive (≥35)	–	37%	100%	100%	–	–	–

Data are shown as median (interquartile range).

*: $P<0.01$ (Day 1 vs Day 15, 29, 61, 82–96, 224–232, or 263)

†: $P<0.01$ (Day 15 vs Day 29)

‡: $P<0.01$ (Day 29 vs Day 61, 82–96, 224–232, or 263)

§: The number of participants tested for humoral responses (IgG-S, IgG-N, and IgM-S).

‖: The number of participants tested for T cell responses (Ag1-Nil and Ag2-Nil).

Figure 1. Humoral responses during and after BNT162b2 mRNA-based SARS-CoV-2 vaccination regimen



Figure 2. SARS-CoV-2 spike specific T cell responses during and after BNT162b2 mRNA-based SARS-CoV-2 vaccination regimen



Figure 3. Correlation between SARS-CoV-2 spike specific IgG titers and T cell responses at each time point



Figure 4. SARS-CoV-2 spike specific IgG titers by background factors